SIMCERE PHARMA Shares Surge Over 3% Following Exclusive Distribution Deal for Novel Topical Treatment

Stock News06-10

SIMCERE PHARMA (HKEX: 02096) shares experienced a notable uptick in afternoon trading, climbing more than 3%. At the time of writing, the stock was up 3.03% to HK$9.87, with a trading turnover of approximately HK$40.1 million.

The price movement follows a recent corporate announcement. The company has entered into an exclusive promotion service agreement with Beijing Puqi Pharmaceutical Technology Co., Ltd. for Pumixitinib Gel.

Under the terms of this new agreement, SIMCERE PHARMA will secure exclusive promotion rights for Pumixitinib Gel across all dermatological indications within mainland China, Hong Kong, and Macau. The topical treatment's New Drug Application for the treatment of atopic dermatitis in adults and adolescents has already been accepted for review by the Center for Drug Evaluation of China's National Medical Products Administration.

Analysts suggest this strategic collaboration is expected to significantly bolster the company's product portfolio and market position within the autoimmune disease therapeutic area.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1105524798?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-10 13:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1105524798","market":"sg","top_or_hot":-1,"title":"SIMCERE PHARMA Shares Surge Over 3% Following Exclusive Distribution Deal for Novel Topical Treatment","media":"Stock News","content":"<p><b>SIMCERE PHARMA</b> (<b>HKEX: 02096</b>) shares experienced a notable uptick in afternoon trading, climbing more than 3%. At the time of writing, the stock was up 3.03% to HK$9.87, with a trading turnover of approximately HK$40.1 million.<br><br>The price movement follows a recent corporate announcement. The company has entered into an exclusive promotion service agreement with Beijing Puqi Pharmaceutical Technology Co., Ltd. for Pumixitinib Gel.<br><br>Under the terms of this new agreement, <b>SIMCERE PHARMA</b> will secure exclusive promotion rights for Pumixitinib Gel across all dermatological indications within mainland China, Hong Kong, and Macau. The topical treatment's New Drug Application for the treatment of atopic dermatitis in adults and adolescents has already been accepted for review by the Center for Drug Evaluation of China's National Medical Products Administration.<br><br>Analysts suggest this strategic collaboration is expected to significantly bolster the company's product portfolio and market position within the autoimmune disease therapeutic area.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SIMCERE PHARMA Shares Surge Over 3% Following Exclusive Distribution Deal for Novel Topical Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSIMCERE PHARMA Shares Surge Over 3% Following Exclusive Distribution Deal for Novel Topical Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-10 13:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>SIMCERE PHARMA</b> (<b>HKEX: 02096</b>) shares experienced a notable uptick in afternoon trading, climbing more than 3%. At the time of writing, the stock was up 3.03% to HK$9.87, with a trading turnover of approximately HK$40.1 million.<br><br>The price movement follows a recent corporate announcement. The company has entered into an exclusive promotion service agreement with Beijing Puqi Pharmaceutical Technology Co., Ltd. for Pumixitinib Gel.<br><br>Under the terms of this new agreement, <b>SIMCERE PHARMA</b> will secure exclusive promotion rights for Pumixitinib Gel across all dermatological indications within mainland China, Hong Kong, and Macau. The topical treatment's New Drug Application for the treatment of atopic dermatitis in adults and adolescents has already been accepted for review by the Center for Drug Evaluation of China's National Medical Products Administration.<br><br>Analysts suggest this strategic collaboration is expected to significantly bolster the company's product portfolio and market position within the autoimmune disease therapeutic area.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"","article_id":"1105524798","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1105524798","pubTimestamp":1781070264,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"SIMCERE PHARMA (HKEX: 02096) shares experienced a notable uptick in afternoon trading, climbing more than 3%. At the time of writing, the stock was up 3.03% to HK$9.87, with a trading turnover of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","BK1574":"生物医药B类股","BK4588":"碎股","VXUS":"国际股票ETF-Vanguard","BK1515":"抗疫概念","BK1583":"高瓴概念","BK1191":"制药","09939":"开拓药业-B","BK4585":"ETF&股票定投概念","02096":"先声药业","BK1161":"生物科技"},"translate_title":"先声药业达成新型局部治疗药物独家分销协议后股价飙升逾3%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"09939":1,"02096":1,"VXUS":1},"content_text":"SIMCERE PHARMA (HKEX: 02096) shares experienced a notable uptick in afternoon trading, climbing more than 3%. At the time of writing, the stock was up 3.03% to HK$9.87, with a trading turnover of approximately HK$40.1 million.The price movement follows a recent corporate announcement. The company has entered into an exclusive promotion service agreement with Beijing Puqi Pharmaceutical Technology Co., Ltd. for Pumixitinib Gel.Under the terms of this new agreement, SIMCERE PHARMA will secure exclusive promotion rights for Pumixitinib Gel across all dermatological indications within mainland China, Hong Kong, and Macau. The topical treatment's New Drug Application for the treatment of atopic dermatitis in adults and adolescents has already been accepted for review by the Center for Drug Evaluation of China's National Medical Products Administration.Analysts suggest this strategic collaboration is expected to significantly bolster the company's product portfolio and market position within the autoimmune disease therapeutic area.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1105524798","isCrawlerRequest":true}